Fierce Pharma

NOVEMBER 17, 2023

Amid a corporate review of AstraZeneca’s global manufacturing and supply network, the company’s Indian subsidiary is planning to close up shop at the “beating heart” of its India operations in Bang | AstraZeneca Pharma India will exit its production plant in Bangalore, India, “in due course,” the company said in a filing.

Manufacturing 253

Manufacturing Networking Pharma 253

Fierce Pharma

NOVEMBER 27, 2023

The gene-editing therapy won a world-first approval in the U.K. earlier this month.

Manufacturing 250

Manufacturing Networking Pharmaceutical 250

Fierce Pharma

NOVEMBER 28, 2023

Monday, during the first meeting of the new White House Council on Supply Chain Resilience, President Biden unveiled nearly 30 actions to bolster production networks across industries. As drug shortages mount in the U.S. with little relief in sight, President Joe Biden has rolled out a slew of efforts to bolster the nation’s supply chains.

Manufacturing 218

Manufacturing Networking Medicine 218

European Pharmaceutical Review

SEPTEMBER 18, 2023

The Cell and Gene Therapy Catapult (CGT Catapult) , supported by Scotland’s national economic development agency, Scottish Enterprise, has launched a new cooperative network to foster collaboration and increase knowledge sharing across the Advanced Therapy Medicinal Products (ATMP) industry in Scotland.

Networking 117

Networking Medicine Manufacturing Medical 117

pharmaphorum

OCTOBER 25, 2024

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.The programme represents the largest capital spend by the UK drugmaker on production capacity to date and will double the size and capacity of GSK's existing medicines and vaccines facility in Marietta, Pennsylvania, (..)

Manufacturing 111

Manufacturing Networking Medicine 111

European Pharmaceutical Review

APRIL 23, 2024

Bristol Myers Squibb (BMS) and Cellares have announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies. The agreement will see BMS use Cellares’ fully automated cell therapy manufacturing platform for the clinical and commercial-scale manufacturing of select CAR T cell therapies.

Manufacturing 96

Manufacturing Networking Patients Pharmaceutical 96

pharmaphorum

JANUARY 24, 2023

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Over the same period, similar countries – including Ireland, France, and Germany – have been moving to boosting manufacturing productivity, output, and exports.

Manufacturing 111

Manufacturing Medicine Government Pharmaceutical manufacturing 111

European Pharmaceutical Review

SEPTEMBER 21, 2023

A new Denmark-based manufacturing facility is set to establish the final development steps and upscaling of cell therapies. Partly due to this and due to the explorative phase cell therapy is in, it is very expensive to develop and manufacture cell therapies, so there simply are not many facilities doing it.”

Manufacturing 116

Manufacturing Leads Networking Pharmaceutical 116

European Pharmaceutical Review

DECEMBER 23, 2022

Our ambition is to build a modern, industry-leading manufacturing network, by bringing together talented people and cutting-edge processes, technologies and data to reliably deliver high quality, affordable and sustainable medicines and vaccines to patients. Standardise manufacturing .

Manufacturing 98

Manufacturing Networking Medicine Electronics 98

European Pharmaceutical Review

MARCH 20, 2024

Lonza has agreed to acquire one of the world’s largest biologics manufacturing sites (by volume), for a total of $1.2 The acquisition of the manufacturing facility will significantly increase Lonza’s capacity of the manufacture of large-scale biologics, to meet demand for commercial mammalian contract manufacturing.

Manufacturing 105

Manufacturing Medicine Networking Pharmaceutical 105

European Pharmaceutical Review

DECEMBER 2, 2022

billion in its manufacturing site in Grange Castle , Dublin, the company’s biggest expansion investment to date in Ireland. A new facility will be built on the site premises, doubling the capacity for biologics manufacturing at the facility. The firm’s manufacturing sites in Grange Castle, Newbridge, Co. Pfizer Inc.

Manufacturing 105

Manufacturing Medicine Networking Medical 105

MedReps

NOVEMBER 21, 2022

You could also apply for jobs available at medical manufacturers straight out of college, hoping you’ll be one of the lucky ones called for an interview. You can always network your way into medical sales. What is Networking? The key to networking, above knowing how to use these connections, is how to make them.

Medical sales 78

Medical sales Networking Sales Medical 78

European Pharmaceutical Review

APRIL 18, 2023

billion and another 200 new jobs is planned for Eli Lilly and Company’s two new pharmaceutical manufacturing sites in Boone County, US. Eli Lilly’s investment here is the largest manufacturing investment at a single location in its history. Students will also be able to access a smart manufacturing lab.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 98

European Pharmaceutical Review

APRIL 15, 2024

billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. Significant” large-scale production capacity will consequently be added to FUJIFILM Diosynth Biotechnologies’ global network. FUJIFILM Corporation is planning to invest $1.2 billion, FUJIFILM confirmed.

Manufacturing 98

Manufacturing Biopharma Networking Pharmaceutical 98

European Pharmaceutical Review

MAY 10, 2023

Sandoz has announced it is investing €25 million in its manufacturing site in Holzkirchen, Germany, to expand its biosimilar development capabilities. First biosimilar to HUMIRA® available in US … The post Sandoz to boost biosimilar development with manufacturing expansion appeared first on European Pharmaceutical Review.

Manufacturing 98

Manufacturing Medicine Networking Biopharma 98

European Pharmaceutical Review

FEBRUARY 5, 2024

Novo Nordisk is set to acquire three fill-finish manufacturing sites from Novo Holdings A/S (Novo Holdings) for $11 billion. This agreement is part of a transaction in which Novo Holdings agreed to acquire the contract development and manufacturing organisation (CDMO) Catalent.

Manufacturing 98

Manufacturing Networking Pharmaceutical 98

European Pharmaceutical Review

SEPTEMBER 28, 2023

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Manufacturing 98

Manufacturing Government Pharmaceutical manufacturing Pharmaceutical 98

European Pharmaceutical Review

FEBRUARY 7, 2024

AstraZeneca has announced a $300 million investment in a US-based manufacturing facility in Rockville, Maryland, which will focus initially on T-cell therapies for oncology indications. Currently, AstraZeneca’s manufacturing sites in the US focus on producing small molecules and biologics, the company highlighted.

Manufacturing 103

Manufacturing Medicine Networking Patients 103

European Pharmaceutical Review

OCTOBER 12, 2023

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Importantly, each site features advanced technologies to support development and manufacture of these therapeutics. Materials and financing costs are high and squeezing manufacturers and their customers alike.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104

European Pharmaceutical Review

MAY 1, 2023

After agreeing to acquire a US-based manufacturing facility and its operations from Novartis, Bristol Myers Squibb (BMS) adds in-house production of viral vectors to its capabilities. This move will support the expansion of the company’s global cell therapy manufacturing network.

Manufacturing 98

Manufacturing Engineering Networking Patients 98

European Pharmaceutical Review

FEBRUARY 27, 2024

It is the company ’s most advanced manufacturing facility to date. “As part of Amgen’s global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines.”

Manufacturing 105

Manufacturing Food and Drug Administration Food Networking 105

European Pharmaceutical Review

NOVEMBER 20, 2023

billion parenteral (injectable) manufacturing site in Alzey, Rhineland-Palatinate, Germany. This includes automation and high-speed manufacturing lines. With the planned additional manufacturing facility in Alzey, the company will operate a total of six manufacturing sites in Europe.

Manufacturing 98

Manufacturing Medicine Biopharma Engineering 98

European Pharmaceutical Review

MARCH 23, 2023

Through its investment of approximately £600 million, Takeda plans to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. This is Takeda’s largest ever investment in manufacturing capacity expansion and will be the largest facility of its kind in Japan.

Manufacturing 89

Manufacturing Networking Medicine Medical 89

European Pharmaceutical Review

JUNE 17, 2024

A portion of the investment, €125 million, is intended to support greater production capacity at its Latina site, which is a key part of the firm’s worldwide supply chain network, the company stated. Johnson & Johnson Innovative Medicine is planning to invest a total of €580 million in Italy over the next five years.

Medicine 97

Medicine Manufacturing Management Government 97

PharmaTech

NOVEMBER 28, 2024

Through this acquisition, the German CDMO expands its global network and adds aseptic fill/finish and lyophilization expertise to its sterile manufacturing capabilities.

Manufacturing 64

Manufacturing Networking Pharma 64

Legacy MEDSearch

DECEMBER 21, 2022

a groundbreaking respiratory support technology company, announced today that it has begun the manufacturing process for the ALICE CPB (Cardiopulmonary Bypass) device (the “ALICE device”) to undergo the Verification and Validation phase prior to its planned 2023 submission to the U.S. Inspira Technologies OXY B.H.N. and Israel.

Manufacturing 98

Manufacturing FDA Food and Drug Administration Medical 98

pharmaphorum

FEBRUARY 5, 2024

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes and obesity drugs.

Manufacturing 105

Manufacturing Networking 105

European Pharmaceutical Review

DECEMBER 30, 2024

It is estimated that only 4,000 doses of chimeric antigen receptor T cell (CAR-T) were manufactured in 2021, despite an eligible patient population of 450,000. 1 It is estimated that only 4,000 doses of chimeric antigen receptor T cell (CAR-T) were manufactured in 2021, despite an eligible patient population of 450,000.

Manufacturing 52

Manufacturing Food and Drug Administration Medicine Training 52

European Pharmaceutical Review

OCTOBER 31, 2024

It pledges to benefit key industry sectors across life sciences including R&D, innovation, manufacturing and medicine. Over the last five years Made Smarter has transformed countless SME manufacturers,” stated Donna Edwards, Director of Made Smarter’s North West adoption programme.

Manufacturing 52

Manufacturing Medical science Medicine Engineering 52

PharmaTech

JUNE 9, 2024

In this asset, you will discover how the Gibco Efficient-Pro system can revolutionize your mAb manufacturing workflow. It provides insights into optimizing CHO cell productivity, enhancing product titers and protein quality, streamlining process efficiency, and leveraging a reliable supply network.

Manufacturing 52

Manufacturing Networking 52

Pharmaceutical Technology

NOVEMBER 14, 2022

BioNTech’s Singapore affiliate BioNTech Pharmaceuticals Asia Pacific has signed an agreement with Novartis Singapore Pharmaceutical Manufacturing to acquire a GMP-certified manufacturing site in the country. . It also has the potential for extension into the manufacturing of other drug classes such as cell therapies. .

Manufacturing 64

Manufacturing Pharmaceutical manufacturing Pharmaceutical Networking 64

Pharma Pathway

MARCH 13, 2023

The Company has its own Research & Development Centre at Kandivli (West), Mumbai, state of the art, Bulk Manufacturing Plant at Ankleshwar and Formulation plant at Dehradun and SEZ, Kandla having approval of MHRA (UK), MCC (SA) and other International Health Authorities. Manager, IT-Networking Engineer Qualification: B.E/

Engineering 56

Engineering Networking Pharma Manufacturing 56

European Pharmaceutical Review

OCTOBER 10, 2023

Set at the world-renowned Silverstone F1 Racetrack on 18 October 2023, it promises to be a day of immersive insights and top rate networking.

Engineering 123

Engineering Networking Manufacturing Consulting 123

European Pharmaceutical Review

JUNE 6, 2024

WuXi Biologics has successfully installed three new sets of 5,000L single-use bioreactors at its MFG20 drug substance manufacturing facility in Hangzhou, China. The new single-use bioreactors at the Hangzhou facility are expected to complete good manufacturing practise (GMP) release later in 2024, the CRDMO confirmed. “The

Manufacturing 98

Manufacturing Government Networking Pharmaceutical 98

European Pharmaceutical Review

APRIL 8, 2024

A study investigating the trend for existing pharmaceutical companies to outsource to contracted development and manufacturing organisations (CDMOs), analysing the position of companies manufacturing monoclonal antibody drugs (mAbs). Yoshiura et al.

Manufacturing 52

Manufacturing Networking Pharmaceutical Marketing 52

European Pharmaceutical Review

AUGUST 11, 2023

Contract development and manufacturing organisation AGC Biologics has completed expansion of its cell and gene therapy (CGT) development and manufacturing site in Milan, Italy. The site was acquired in July 2020 and was the first cell and gene therapy site approved in Europe for GMP manufacturing of clinical and commercial supplies.

Manufacturing 52

Manufacturing Networking Management Pharmaceutical 52

European Pharmaceutical Review

DECEMBER 5, 2024

Through a new agreement, Eli Lilly and Company and contract development and manufacturing organisation (CDMO) Cambrex will enable external biotech collaborators to accelerate their product development. Collaborators can also access additional support will be provided by Cambrex’s network.

Manufacturing 52

Manufacturing Pharmaceutical products Networking Pharmaceutical 52